Home › Gastrointestinal Cancers › Illinois › Chicago
Gastrointestinal Cancers clinical trials in Chicago, IL
5 studies for Gastrointestinal Cancers are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 3
- Illinois Cancer Specialists, Chicago
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
RecruitingPhase 3
- GSK Investigational Site, Chicago
- GSK Investigational Site, Chicago
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
RecruitingPhase 1/2
- Northwestern University, Chicago
Telephone Support in Advanced Gastrointestinal Cancer
Recruiting
- Northwestern Medicine, Chicago
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
- University of Chicago, Chicago
Gastrointestinal Cancers trials in other cities
- Houston, TX21 studies
- Boston, MA15 studies
- New York City, NY12 studies
- Nashville, TN10 studies
- Los Angeles, CA9 studies
- Durham, NC8 studies
- Dallas, TX8 studies
- Baltimore, MD8 studies
- Cincinnati, OH8 studies
- Arlington, VA8 studies
- San Antonio, TX7 studies
- Baldwin Park, CA7 studies
Other studies in Chicago
- Non-Small Cell Lung Cancer61 studies
- Breast Cancer58 studies
- Cancer (all types)51 studies
- Metastatic Cancer45 studies
- Prostate Cancer45 studies
- Obesity41 studies
- Lung Cancer41 studies
- Ovarian Cancer36 studies
- Stroke34 studies
- Colorectal Cancer33 studies
- Heart Failure31 studies
- Overweight28 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.